C-CYTRRelation Therapeutics
single-cell multi-omics, functional assays, machine learning
discoverydiscovering
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CYTR
C-CYTRC-CYTRsingle-cell multi-omics, functional assays, machine learning
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Relation Therapeutics single-cell multi-omics, functional assays, machine learning
Relation Therapeutics is an end-to-end biotech developing transformational medicines with technology at its core. The company uses single-cell multi-omics directly from patient tissue, functional assays and machine learning to understand disease biology and identify druggable targets. Its Lab-in-the-Loop integrates single-cell analysis, genomics and machine learning, and the site identifies osteoporosis as its first indication.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Relation Therapeutics — Early mechanism · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic